Payer reimbursement pressures are leading to radical changes in the oncology treatment, but there is a need for improved guidance for providers in assessing drug value, according to an article in JMCP.
Payer reimbursement pressures are leading to radical changes in the oncology treatment, but there is a need for improved guidance for providers in assessing drug value, according to an article in JMCP.
